Psychiatry
We are committed to the research and discovery of novel pathways and therapies to address some of the world's most serious psychiatric conditions. Our goal is to develop therapies that transform the lives of people living with these conditions.
A Decade of Innovation
Over the past 10 years, we have made it our mission to serve the psychiatric community of more than 700 thousand people living with bipolar disorder and schizophrenia in Canada. We continue to investigate some of the world's most serious mental disorders to help improve the lives of patients with these conditions.
Bipolar Depression*
29M
Worldwide
322K
Canada
Schizophrenia*
20M
Worldwide
380K
Canada
Our Medicines
LATUDA® (lurasidone HCl) is indicated:
- for the management of the manifestations of schizophrenia.
- as monotherapy or as adjunctive therapy with lithium or valproate for the acute management of depressive episodes associated with bipolar I disorder.